Biotechnology News and Research

RSS

Nuevolution partners with Novartis for drug research

Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Novartis.

31 Aug 2009

Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Dr. Christian Torp-Pedersen is scheduled to present detailed findings from the Phase 2b clinical trial of vernakalant (oral) at the European Society of Cardiology (ESC) Congress 2009, being held in Barcelona, Spain from August 29 to September 2, 2009.

29 Aug 2009

NASDAQ Stock Market issues delisting notice to American Bio Medica Corporation

American Bio Medica Corporation (NASDAQ: ABMC) announced today that, on August 25, 2009, it received a delisting notice from the NASDAQ Stock Market, for failure to regain compliance with the minimum bid price requirement pursuant to Listing Rule 5550(a)(2).

From Medica Corporation 29 Aug 2009

Cancer Immunotherapy Index of ten cancer immunotherapy stocks increases by 23%

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector.

29 Aug 2009

Office of Orphan Products Development of the FDA grants Orphan Drug Designation to Quinazoline495

Families of Spinal Muscular Atrophy (Libertyville, IL) announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted Orphan Drug Designation to Quinazoline495 for the treatment of Spinal Muscular Atrophy.

29 Aug 2009

SABiosciences included in The Scientist Magazine's 2009 Top 30 Best Places to Work list

SABiosciences announces its inclusion on The Scientist Magazine's 2009 Top 30 Best Places to Work Industry Survey. Best Places to Work is an annual survey highlighting those companies with the most positive work environment, dedicated management, and innovative ways to motivate their workforce.

29 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

New compound discovered by Scripps scientists offers a novel template for drug development

Scientists at Scripps Institution of Oceanography at UC San Diego and their colleagues at Creighton University have deciphered the highly unusual molecular structure of a naturally produced, ocean-based compound that is giving new understanding of the function of mammalian nerve cells.

29 Aug 2009

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Geneuity Clinical Research Services announces the recent validation and use in clinical trials of two human biomarker assays that play a key role in the early detection of kidney damage.

29 Aug 2009

Scientists study the impact of nerve growth factors for treating Parkinson's disease

Scientists in the Academy of Finland's Neuroscience Research Programme have reported promising new results with potential implications for the treatment of Parkinson's disease. They have been studying the impacts of nerve growth factors in the treatment of PD, and their latest results show that a certain growth factor can be used to halt the progress of damage brought on by a nerve poison and possibly even restore the function of damaged cells.

28 Aug 2009

Bavarian Nordic generates a revenue of DKK 33 million in the first half of 2009

In the first half of 2009 Bavarian Nordic generated revenue of DKK 33 million and recorded a loss before tax of DKK 188 million. As of 30 June 2009 the Group's net free liquidity was DKK 489 million.

28 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

Researches report new results that may help in better treament for patients with Parkinson's disease

28 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

ASHG 2009 Annual Meeting to discuss the cutting-edge developments in human genetics and genomics research

The world's top scientists and clinicians in the human genetics field will gather in Honolulu, Hawaii to present their latest research findings at the 59th Annual Meeting of the American Society of Human Genetics, from Tuesday, October 20, through Saturday, October 24, 2009, at the Hawaii Convention Center.

28 Aug 2009

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.

28 Aug 2009

Iowa researchers modify siRNA for impacting targeted cells in cancer treatment

Small interfering RNA (siRNA), a type of genetic material, can block potentially harmful activity in cells, such as tumor cell growth. But delivering siRNA successfully to specific cells without adversely affecting other cells has been challenging.

28 Aug 2009

Fast Forward selects IntraLinks to support its funding effort

IntraLinks®, the leading provider of critical information exchange solutions, today announced that Fast Forward™ has selected IntraLinks to help streamline the collection, distribution and tracking of information to support their funding of multiple biotechnology and pharmaceutical companies working on new Multiple Sclerosis (MS) treatments.

28 Aug 2009

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.

28 Aug 2009

Scientists discover the vulnerability of old people to cancer and skin infections

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have discovered why older people may be so vulnerable to cancer and infections in the skin. The team from UCL has shown in human volunteers that defective immunity in the skin is caused by an inability to mobilise essential defences that would otherwise recognise threats and clear them before irreparable damage is done.

28 Aug 2009

Biotechnology News and Research

Nuevolution partners with Novartis for drug research

Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009

NASDAQ Stock Market issues delisting notice to American Bio Medica Corporation

Cancer Immunotherapy Index of ten cancer immunotherapy stocks increases by 23%

Office of Orphan Products Development of the FDA grants Orphan Drug Designation to Quinazoline495

SABiosciences included in The Scientist Magazine's 2009 Top 30 Best Places to Work list

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

New compound discovered by Scripps scientists offers a novel template for drug development

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Scientists study the impact of nerve growth factors for treating Parkinson's disease

Bavarian Nordic generates a revenue of DKK 33 million in the first half of 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Researches report new results that may help in better treament for patients with Parkinson's disease

Thrombogenics issues business update and half year results

ASHG 2009 Annual Meeting to discuss the cutting-edge developments in human genetics and genomics research

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

Iowa researchers modify siRNA for impacting targeted cells in cancer treatment

Fast Forward selects IntraLinks to support its funding effort

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Scientists discover the vulnerability of old people to cancer and skin infections

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News